AACR21: AstraZeneca unveils next-gen PARP inhibitor, looking to follow up on success of first-gen success story Lynparza
AstraZeneca’s PARP inhibitor Lynparza has raced out to blockbuster sales on the premise of killing tumor cells by inhibiting their ability to adequately heal. But Lynparza isn’t a perfect molecule, and the British drugmaker is now rolling out a potential successor drug it hopes can achieve similar efficacy without the notorious side effects.
AstraZeneca rolled out early data on its PARP1-selective, next-gen inhibitor AZD5305 at the virtual AACR meeting Saturday, hoping to highlight the drug’s chances at following up — and improving — the science behind blockbuster drug Lynparza.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.